GammaTile(R) Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors.

GT Medical Technologies has announced that it has enrolled its 100th patient in the ROADS clinical study, which is a randomized control trial comparing the use of GammaTile with stereotactic radiotherapy for newly diagnosed metastatic brain tumors. The trial aims to measure progression-free survival, overall survival, quality of life, neurocognitive status, and physical function over a three-year period. GammaTile is a bioabsorbable collagen tile that delivers radiation immediately at the time of surgery, targeting residual cancer cells while minimizing harm to healthy brain tissue. The study began in 2021 and is expected to be completed by December 2024. [Extracted from the article]

Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)